Press Release

Press Release

Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting

Cambridge, MA – November 1, 2017 – Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative bone marrow transplant for more patients, today announced that the Company will present clinical data from its stem cell expansion program and insights into its preclinical research at the 59th annual meeting of the American Society of Hematology (ASH), taking place December 9th through 12th in Atlanta, Ga.

“Magenta Therapeutics is developing new, transformative drugs to extend the curative potential of bone marrow transplant and cell therapies to more patients. We are excited to present data at ASH this year that highlight our stem cell expansion and mobilization programs, as well as a subset of our antibody-based bone marrow transplant conditioning programs,” said Michael Cooke, Ph.D., chief scientific officer, Magenta Therapeutics. “We are also looking forward to the presentation of clinical data from our most advanced program in stem cell expansion, MGTA-456, which has previously delivered promising results in a Phase 2 study.”

Oral Presentations:

Phase 2 Trials with MGTA-456, Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery in Patients Following Myeloablative or Non-Myeloablative Conditioning (Abstract #662)

Presenter: John Wagner, M.D., Director, Blood and Marrow Transplantation Division, University of Minnesota
Session Name: 721 Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Alternative Donor Transplants
Session Date: Monday, December 11, 2017
Session Time: 10:30 AM – 12:00 PM
Presentation Time: 10:45 AM
Room: Georgia World Congress Center, Bldg C, Lvl 2, C202-204

Phenotype Does Not Always Equal Function: HDAC Inhibitors and UM171, But Not SR1, Lead to Rapid Upregulation of CD90 on Non-Engrafting CD34+CD90-Negative Human Cells (Abstract #659)

Presenter: Kevin Goncalves, Ph.D., scientist, Magenta Therapeutics
Session Name: 711. Cell Collection and Processing: Optimization of Hematopoietic Graft Using Small Molecules in Culture
Session Date: Monday, December 11, 2017
Session Time: 10:30 AM – 12:00 PM
Presentation Time: 11:30 AM
Room: Georgia World Congress Center, Bldg B, Lvl 2, B216-B217

Poster Presentations:

Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplant Using a Human Antibody Drug Conjugate Targeting C-KIT (Abstract #1894)

Presenter: Adam Hartigan, Ph.D., senior scientist, Magenta Therapeutics
Session Name: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I
Date: Saturday, December 9, 2017
Presentation Time: 5:30 PM – 7:30 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

The Combination of GROb and AMD3100 leads to Rapid and Robust Mobilization of Hematopoietic Stem Cells in Nonhuman Primates (Abstract #1920)

Presenter: Patrick Falahee, Ph.D., scientist, Magenta Therapeutics
Session Name: 711. Cell Collection and Processing: Poster I
Date: Saturday, December 9, 2017
Presentation Time: 5:30 PM – 7:30 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Aryl Hydrocarbon Receptor Antagonists Expand Adult Hematopoietic Stem Cells from Mobilized Peripheral Blood and Bone Marrow and Increase the Dose of CRISPR/Cas9 Gene-Edited NSG-Repopulating Cells (Abstract #3341)

Presenter: Megan Hoban, Ph.D., scientist, Magenta Therapeutics
Session Name: 801. Gene Therapy and Transfer: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

About Magenta Therapeutics|

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize stem cell transplantation for patients with immune and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to stem cell therapies to change patients’ lives. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.

Contact
Magenta Therapeutics:
Manisha Pai, Vice President, Communications & Investor Relations
857-242-1155
mpai@magentatx.com

Dr. Gardner continued, “There has been terrific innovation in stem cell science recently, and it is time to bring this forward to patients.  During the past year, we have incubated Magenta with Third Rock and Atlas, and conducted extensive diligence on the key science in collaboration with many leading experts in the field. We have recruited a strong team at Magenta and are working with an experienced set of founders and advisors around an important vision in medicine. Our ultimate goal is to reboot the blood and immune systems safely to make a significant impact on the overall quality of life for a much broader group of patients that can benefit from transplant.”

Leading Scientific Cofounders

Magenta was founded by internationally recognized experts in stem cell medicine.

The Magenta Mission

The current standard of clinical practice for stem cell transplantation is based on science developed decades ago. With recent breakthroughs and significant clinical opportunity, Magenta aims to broaden the range of patients eligible for transplant by improving three key aspects of the procedure: patient preparation using targeted antibodies, stem cell harvesting using new biologic agents, and increasing stem cell numbers by targeting self-renewal pathways. More details of the science and programs will be forthcoming as the Company advances.

David Scadden, Magenta’s chief scientific advisor, chair of the scientific advisory board and cofounder commented: “Stem cell transplants are curative. With new gene therapy and gene editing technologies and emerging clinical experience in autoimmune diseases, more patients with more diseases can be helped or cured. We think we can make stem cell transplants safer and more efficient and change the conversation with patients from risk-focused to benefit-focused. Our goal is to make transplantation a desired early option for people with many blood and immune disorders.”

Magenta Therapeutics is led by a management team with deep scientific expertise and demonstrated success in drug discovery and development. In addition to Dr. Gardner, the company’s leadership includes Michael Cooke Ph.D., chief scientific officer; Bastiano Sanna Ph.D., chief operating officer; and Christina Isacson Ph.D., vice president, head of business development. The board of directors will be led by Mike Bonney, former CEO of Cubist, as executive chairman, Alexis Borisy from Third Rock Ventures, Bruce Booth from Atlas Venture and Tom Daniel, former president of research and early development at Celgene, as independent director.  These groups have been working closely together from the inception of the company and provide broad leadership and a shared vision.

The Series A round also includes GV (formerly Google Ventures), Access Industries (Blavatnik Group) and Partners Innovation Fund. Through a license agreement with Harvard University, Magenta has access to a portfolio of breakthrough stem cell technologies developed at Harvard, Massachusetts General Hospital, and Boston Children’s Hospital.

About Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.

About Third Rock Ventures

Third Rock Ventures is a leading healthcare venture firm focused on investing and launching companies that make a difference in people’s lives. The Third Rock team has a unique vision for ideating and building transformative healthcare companies. Working closely with our strategic partners and entrepreneurs, Third Rock has an extensive track record for managing the value creation path to deliver exceptional performance. For more information, please visit the firm’s website at www.thirdrockventures.com.

About Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.  For more information, please visit www.atlasventure.com.

####

Magenta Media Contact:
Dan Budwick, Pure Communications, Inc.
(973) 271-6085
dan@purecommunications.com